314 related articles for article (PubMed ID: 18342102)
1. [Cutaneous side effects of sorafenib and sunitinib].
Autier J; Mateus C; Wechsler J; Spatz A; Robert C
Ann Dermatol Venereol; 2008 Feb; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
[No Abstract] [Full Text] [Related]
2. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
[No Abstract] [Full Text] [Related]
3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
4. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Wollenberg A; Staehler M; Eames T
Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
McLellan B; Kerr H
Dermatol Ther; 2011; 24(4):396-400. PubMed ID: 21910797
[TBL] [Abstract][Full Text] [Related]
6. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor DR
J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
[No Abstract] [Full Text] [Related]
7. Chemotherapeutic agents and the skin: An update.
Heidary N; Naik H; Burgin S
J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
[TBL] [Abstract][Full Text] [Related]
8. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
9. [Cutaneous side effects of antiangiogenic agents].
Robert C
Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
[TBL] [Abstract][Full Text] [Related]
10. [Dermatologic side effects induced by new angiogenesis inhibitors].
Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C
Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
[TBL] [Abstract][Full Text] [Related]
11. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
12. Reversible cardiomyopathy associated with sunitinib and sorafenib.
Uraizee I; Cheng S; Moslehi J
N Engl J Med; 2011 Oct; 365(17):1649-50. PubMed ID: 22030001
[No Abstract] [Full Text] [Related]
13. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
[No Abstract] [Full Text] [Related]
14. [Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Bednaríková D; Kocák I
Klin Onkol; 2010; 23(5):300-5. PubMed ID: 21061680
[TBL] [Abstract][Full Text] [Related]
15. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Robert C; Soria JC; Spatz A; Le Cesne A; Malka D; Pautier P; Wechsler J; Lhomme C; Escudier B; Boige V; Armand JP; Le Chevalier T
Lancet Oncol; 2005 Jul; 6(7):491-500. PubMed ID: 15992698
[TBL] [Abstract][Full Text] [Related]
17. Risk of bleeding not increased by sorafenib or sunitinib.
Minor DR
Lancet Oncol; 2010 Feb; 11(2):112-3; author reply 113. PubMed ID: 20152763
[No Abstract] [Full Text] [Related]
18. [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Staehler M; Haseke N; Schöppler G; Stadler T; Heinemann G; Stief CG
Urologe A; 2006 Oct; 45(10):1333-42; quiz 1343. PubMed ID: 17021905
[TBL] [Abstract][Full Text] [Related]
19. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
[No Abstract] [Full Text] [Related]
20. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Porta C; Paglino C; Imarisio I; Bonomi L
Clin Exp Med; 2007 Dec; 7(4):127-34. PubMed ID: 18188524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
